Canine CAR-T Development Service for Hematologic Malignancies

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Powered by our in-house scientists and advanced technological platforms, Creative Biolabs is committed to providing canine CAR-T development service to best suit the client's program requirements.

Utilizing Spontaneous Tumors in Canine to Improve CAR-T Therapy for Human Cancers

Compared with other mammals, the canine genome shares greater homology with the human genome, along with a very high degree of similarity in the characteristics of tumorigenesis. Using the characteristics of spontaneous cancer in dogs for CAR-T evaluation will promote the development of CAR-T cell therapy for cancer, and it is expected to improve the evaluation parameters for preclinical CAR-T cell product selection.

Fig.1 Naturally occurring cancers in dogs facilitate CAR-T development. (Mata & Gottschalk, 2016)

Our Canine CAR-T Development Service for Hematologic Malignancies

Hematologic malignancies are a large group of cancers affecting the blood, bone marrow, and lymph nodes, afflicting millions of adults and children every year, and are often fatal. With our years of experience in the CAR-T field, Creative Biolabs is committed to offering canine CAR-T development services for hematologic malignancies. Our service is featured with the following items.

A Wide Range of Hot Targets for Hematologic Malignancies

As more and more hematologic malignancies markers have been discovered, we have launched canine CAR-T development services for hematologic malignancies with a lot of popular targets. Here are some popular targets you can choose to design for, including but not limited to:

Fig.2 Popular targets profile for hematologic malignancies. (Creative Biolabs)

A Variety of CAR Design and Construction Strategies

For CAR design and construction, we offer classic and special CAR design and construction solutions for clients to reference and choose from. The following are some of our CAR designs, including but not limited to:

CAR Design & Construction
TanCAR Construction	VHH-based CAR Construction	CRISPR/Cas9-based CAR Construction	Modular CAR (modCAR) Construction
CD3ε-Based CAR Design & Construction	Adnectin-Based CAR Construction	HiCAR Construction Service	Dual / Triple Antigen Combinations CAR Construction
Smarter™ Armored CAR Construction	Smarter™ Marked CAR Construction	Smarter™ Switch CAR-T Construction	Smarter™ 7 × 19 CAR Construction

Comprehensive Services to Assist Canine CAR-T Development Targeting Hematologic Malignancies

We offer the following processes, from target selection and design optimization to in vitro and in vivo functional validation. At the same time, we have a professional technical team to support the optimization and implementation of the project for every step of the process.

Fig.3 The flowchart of CAR-T development services. (Creative Biolabs)

Published Data

Paper Title: Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma
Summary: The researchers designed and established autologous cCD20-ζ CAR-T cells using the mRNA electroporation method. For in vivo functional evaluation, autologous cCD20-ζ CAR-T cells were administered to dogs with relapsed B-cell lymphoma and showed modest anti-tumor activity.
Technology: RNA-transfected
Cell Type: Canine T cells
Results:

Fig.4 The cCD20-ζ CAR Design. (Panjwani, et al., 2016)

Fig.5 In vitro functional assessment of cCD20-ζ CAR-T cocultured with tumor cell. (Panjwani, et al., 2016)

Fig.6 In vivo functional evaluating cCD20-ζ CAR-T in dogs with spontaneous cancer. (Panjwani, et al., 2016)

For more detailed information about canine CAR-T development targeting hematologic malignancies, please feel free to contact us or directly sent us an inquiry.

References

Mata, M.; Gottschalk, S. Man's best friend: utilizing naturally occurring tumors in dogs to improve chimeric antigen receptor T-cell therapy for human cancers. Molecular Therapy. 2016, 24(9):1511-2.
Panjwani, M.K.; et al. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Molecular Therapy. 2016, 24(9):1602-14.